Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment - Scorecard - MDSpire

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment

  • By

  • Heather E. Hsu

  • Sara Lodi

  • Shapei Yan

  • Benjamin J. Bovell-Ammon

  • Paul J. Christine

  • Alyssa S. Tilhou

  • Dana Bernson

  • Patricia Novo

  • Joshua D. Lee

  • John Rotrosen

  • Jane M. Liebschutz

  • Alexander Y. Walley

  • Marc R. Larochelle

  • July 14, 2026

Share

Clinical Scorecard: Comparison of Buprenorphine-Naloxone and Extended-Release Naltrexone After Opioid Withdrawal Management

At a Glance

CategoryDetail
ConditionOpioid Use Disorder
Key MechanismsBuprenorphine-naloxone and XR naltrexone are FDA-approved medications for opioid use disorder, aimed at reducing opioid use and improving treatment retention.
Target PopulationIndividuals 18 years or older discharged from voluntary medically managed opioid withdrawal programs.
Care SettingCommunity-based medically managed opioid withdrawal programs.

Key Highlights

  • Buprenorphine-naloxone and XR naltrexone are effective in managing opioid use disorder.
  • Observational studies suggest lower overdose rates with buprenorphine-naloxone compared to XR naltrexone.
  • The study utilized a target trial emulation framework to compare treatment outcomes.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of opioid use disorder based on clinical criteria.

Management

  • Initiation of buprenorphine-naloxone or XR naltrexone within 28 days of MMOW discharge.

Monitoring & Follow-up

  • Monitor for all-cause mortality and nonfatal opioid overdose within 24 weeks of discharge.

Risks

  • Increased overdose risk has been observed in XR naltrexone group compared to buprenorphine-naloxone.

Patient & Prescribing Data

Individuals with opioid use disorder discharged from medically managed withdrawal programs.

Treatment strategies include buprenorphine-naloxone and XR naltrexone, with considerations for patient history and eligibility.

Clinical Best Practices

  • Utilize a target trial emulation framework for observational studies.
  • Ensure comprehensive eligibility criteria to minimize bias in treatment comparisons.
  • Incorporate race and ethnicity data to adjust for structural factors affecting treatment outcomes.

Related Resources & Content

Original Source(s)

Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment

  • by Heather E. Hsu, Sara Lodi, Shapei Yan, Benjamin J. Bovell-Ammon, Paul J. Christine, Alyssa S. Tilhou, Dana Bernson, Patricia Novo, Joshua D. Lee, John Rotrosen, Jane M. Liebschutz, Alexander Y. Walley, Marc R. Larochelle

  • July 14, 2026

Related Content

Factors associated with infection-related hospitalisations in severe mental illness: a retrospective cohort study

Secretary Kennedy Announces Over $700 Million in New Funding to Address Mental Illness, Addiction, Homelessness

Former Dentist Ordered to Pay for Unlawful Prescribing

The judgment stemmed from controlled-substance prescriptions issued after William C. Gardner, DDS, no longer held the state licensure required for federal prescribing authority.